Finding biomarkers to predict treatment benefits for a specific type of cancer
Official title: Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
Funded at Sloan-Kettering Inst Can Research · NIH-11086685 · Data updated 2026-11-12
This study is looking at a new treatment approach for people with a rare type of cancer called liposarcoma, by combining two medications to see if they can work better together, and it aims to find out which patients might benefit the most from this combination.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 15, 2022 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $625,681 |
| NIH project number | 5R01FD007528-04 |
| Project ID | NIH-11086685 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients diagnosed with locally advanced or metastatic well-differentiated or dedifferentiated liposarcoma.
✕Less likely to help
Patients with other types of cancers or those who do not have the specific genetic markers associated with this research may not benefit.
What this research studies
This research focuses on patients with well-differentiated or dedifferentiated liposarcoma, a rare cancer that often does not respond to standard chemotherapy. The study aims to combine a CDK4/6 inhibitor, which has shown some effectiveness in stabilizing disease, with a PD1 checkpoint inhibitor to enhance treatment responses. Researchers will investigate the biological markers that can predict which patients are most likely to benefit from this combination therapy. By understanding the mechanisms of response and resistance, the goal is to improve patient outcomes and tailor treatments more effectively.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with a rare and challenging cancer.
How similar studies have gone: While the combination of CDK4/6 inhibitors and checkpoint inhibitors has shown promise in other cancers, this specific approach in dedifferentiated liposarcoma is relatively novel.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: D'angelo, Sandra P — Sloan-Kettering Inst Can Research
- Study coordinator: D'angelo, Sandra P
Related research
Other NIH-funded projects on the same topics.
-
Dissecting how liposarcoma cells differentiate and interact with immune cells to find new therapies
This grant explores how liposarcoma cancer cells differentiate and how immune cells in the tumor environment influence progression, with the aim of finding new treatment options for patients.
-
Preclinical mouse models of liposarcoma for immuno-oncology applications
A research grant is studying immune-related ways to understand and treat liposarcoma using a specially engineered mouse model that mimics human tumors.
-
Improving CDK4/6 therapy for liposarcoma by understanding resistance
This project tests a combination therapy to overcome resistance to CDK4/6 inhibitors in patients with dedifferentiated liposarcoma and aims to improve treatment results.
-
Improving treatment for liposarcoma by understanding drug resistance
This study is looking to help patients with dedifferentiated liposarcoma by finding better ways to use a cancer treatment called CDK4/6 inhibitors, especially for those who don’t respond well to it, by testing a combination of two drugs, palbociclib and mirdametinib, to see if it can improve their treatment results.
-
Investigating the immune environment of liposarcoma using genetically modified mice
This study is looking at how certain immune cells, called memory T cells, work in the environment of liposarcoma tumors to find new ways to improve treatment for patients with this type of cancer.
-
Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma
This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.